1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
BUSINESS
Kyowa Kirin’s Overseas Sales Ratio Nears 50%, Driven by Crysvita in Europe, US: January-September
Kyowa Kirin’s group sales grew 3.8% to 234 billion yen in the first nine months of 2020, driven by robust performances overseas, despite a contraction in revenue in Japan due to the drug price cut in April and the switch…
To read the full story
Related Article
- Kyowa Kirin’s 2020 Sales Rise 4.1% on Growth of 3 Strategic Products
February 5, 2021
BUSINESS
- CureApp’s Alcoholism Therapy App Approved in Japan
February 19, 2025
- Japan Approves Shionogi’s Therapy App for Pediatric ADHD
February 19, 2025
- Kyorin Nabs Japan Option for Cyrano’s Post-Viral Smell Loss Drug
February 19, 2025
- COVID Shot Kostaive Lands EU Approval, 1st Nod Outside Japan
February 19, 2025
- Boehringer Files Zongertinib in Japan for HER2 Lung Cancer
February 19, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…